1.
Ambrosio LF, Volpini X, Quiroz JN, et al. Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease. Frontiers in immunology. 2023;14:1267641. doi:10.3389/fimmu.2023.1267641.
1.
Mehr AP, Tran MT, Ralto KM, et al. De novo NAD biosynthetic impairment in acute kidney injury in humans. Nat Med. 2018;24(9):1351-1359. doi:10.1038/s41591-018-0138-z.
1.
Natividad JM, Agus A, Planchais J, et al. Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. Cell Metab. 2018;28(5):737-749.e4. doi:10.1016/j.cmet.2018.07.001.
1.
Dolciami D, Gargaro M, Cerra B, et al. Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist. ChemMedChem. 2018;13(3):270-279. doi:10.1002/cmdc.201700669.
1.
van Laarhoven A, Dian S, Aguirre-Gamboa R, et al. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study. Lancet Infect Dis. 2018;18(5):526-535. doi:10.1016/S1473-3099(18)30053-7.
1.
Qi Q, Hua S, Clish CB, et al. Plasma Tryptophan-Kynurenine Metabolites Are Altered in Human Immunodeficiency Virus Infection and Associated With Progression of Carotid Artery Atherosclerosis. Clin Infect Dis. 2018;67(2):235-242. doi:10.1093/cid/ciy053.
1.
Rothhammer V, Borucki DM, Tjon EC, et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557(7707):724-728. doi:10.1038/s41586-018-0119-x.
1.
Yu E, Papandreou C, Ruiz-Canela M, et al. Association of Tryptophan Metabolites with Incident Type 2 Diabetes in the PREDIMED Trial: A Case-Cohort Study. Clin Chem. 2018;64(8):1211-1220. doi:10.1373/clinchem.2018.288720.
1.
Schwieler L, Samuelsson M, Frye MA, et al. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. J Neuroinflammation. 2016;13(1):51. doi:10.1186/s12974-016-0517-7.